Drugs / EGFR IL12 CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03542799 | May 2018 → May 2020 | colorectal cancer | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFR -IL12 -CART | “This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR -IL12 -CART) cells in metastatic...” NCT03542799 ↗ |
| Action | Deplete | “in order to tells the T cells to recognize their target tumor cells and potentially kill them” NCT03542799 ↗ |
| Modality | Cell therapy | “CART cells will then be expanded in vitro and then administered to subjects.” NCT03542799 ↗ |
| Target | EGFR | “This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR -IL12 -CART) cells in metastatic...” NCT03542799 ↗ |